Earlier Agility reports
Goal: to enable the rapid assessment of the biological impacts of new variants of SARS-CoV-2.
Aims of the Agility project:
- Rapid identification of new variants of SARS-CoV-2 that may impact COVID-19 vaccines and countermeasures
- Comparative neutralisation testing of identified variants of concern using a panel of sera and WHO International antibody standard
- Assessment of pathogenesis of variants of concern in relevant SARS-CoV-2 animal models
- Timely reports and information sharing on the biological activity (antigenic characteristics and pathogenesis in animals) of emerging variants
- Predictability and comparability achieved through standard procedures and parallel testing in 2 independent laboratories